On Apr. 15, 2025, Moderna announced that its manufacturing facility in Harwell, Oxfordshire, the Moderna Innovation and Technology Centre (MITC), had been granted a Manufacturer’s/Importer’s Authorisation (MIA) by the Medicines and Healthcare products Regulatory Agency (MHRA).

With the manufacturer’s license in place, the company can move forward with commercial mRNA vaccine manufacture, which will be subject to the standard regulatory review processes with the MHRA. This key milestone follows a successful inspection confirming compliance with the principles and guidelines of Good Manufacturing Practice (GMP), enabling the MITC to become fully operational.

The establishment of the MITC is part of a ten-year strategic partnership between Moderna and the UK Government, managed by the UK Health Security Agency (UKHSA). The partnership aims to boost
pandemic preparedness by on shoring vaccine production and securing priority access to mRNA vaccines while strengthening the UK’s global leadership in clinical research, scientific innovation and skills development.

This broader collaboration goes beyond manufacturing to strengthen long-term resilience and rapid response capabilities, including the ability to produce at least 250 million doses during a pandemic
for the NHS and UK public.

This UK facility and additional sites in Australia and Canada will form a network of advanced manufacturing hubs that collectively strengthen global pandemic readiness. Each site is strategically placed to maximise geographic coverage and minimise response times, ensuring that vaccines and therapeutics can be distributed quickly and efficiently where needed.